摘要
多发性硬化(MS)是一种免疫介导中枢神经系统脱髓鞘疾病(中枢神经系统)。免疫细胞病理学女士的重要性是由临床数据连接T细胞和B细胞的损耗,或迁移进入大脑的预防显著减少复发和发展新的病变。体外研究、临床前动物模型和令人鼓舞的数据与anti-IL-17A抗体secukinumab小概念验证研究,表明,IL-17A关键白介素与许多炎症和自身免疫性疾病,可能参与女士不仅参与适应性免疫反应细胞如Th17细胞和细胞毒性T细胞,或先天免疫反应如mucosa-associated不变的T细胞和γδT细胞(MAIT),中枢神经系统也居民细胞如星形胶质细胞和少突胶质细胞可能导致当地IL-17A的生产。IL-17A加强与其他促炎细胞因子,诱导其他细胞因子的释放,介质的组织损伤和趋化因子,招募新的炎症细胞。IL-17A小胶质细胞的功能造成不利影响,星形胶质细胞,少突胶质细胞、神经元,神经细胞和内皮细胞前体。封锁IL-17A可能有利于医学患者不仅通过抑制炎症和组织破坏,而且还通过提高修复过程。
关键词: IL-17、IL17RA IL-17RC
图形摘要
Current Drug Targets
Title:IL-17A and Multiple Sclerosis: Signaling Pathways, Producing Cells and Target Cells in the Central Nervous System
Volume: 17 Issue: 16
Author(s): Frank Kolbinger, Christine Huppertz, Anis Mir, Franco Di Padova
Affiliation:
关键词: IL-17、IL17RA IL-17RC
摘要: Multiple sclerosis (MS) is an immune mediated demyelinating disease of the central nervous system (CNS). The importance of immune cells to MS pathology is supported by clinical data linking the depletion of T and B cells, or the prevention of their migration into the brain with significant reduction in relapses and development of new lesions. In vitro studies, preclinical animal models and encouraging data with the anti-IL-17A antibody secukinumab in a small proof of concept study in man, indicate that IL-17A, a key interleukin associated with many inflammatory and autoimmune diseases, may be involved in MS. Not only cells involved in adaptive immune responses such as Th17 cells and cytotoxic T cells, or innate immune responses such as mucosa-associated invariant T (MAIT) cells and γδT cells, but also CNS resident cells such as astrocytes and oligodendrocytes might contribute to the local production of IL-17A. IL-17A synergizes with other proinflammatory cytokines, by inducing the release of additional cytokines, mediators of tissue damage and chemokines, that recruit new inflammatory cells. IL-17A adversely affects the functions of microglia, astrocytes, oligodendrocytes, neurons, neural precursor cells and endothelial cells. Blockade of IL-17A might be beneficial to MS patients not only by inhibiting inflammation and tissue destruction, but also by enhancing repair processes.
Export Options
About this article
Cite this article as:
Frank Kolbinger, Christine Huppertz, Anis Mir, Franco Di Padova , IL-17A and Multiple Sclerosis: Signaling Pathways, Producing Cells and Target Cells in the Central Nervous System, Current Drug Targets 2016; 17 (16) . https://dx.doi.org/10.2174/1389450117666160307144027
DOI https://dx.doi.org/10.2174/1389450117666160307144027 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chinese Herbs and Herbal Extracts for Neuroprotection of Dopaminergic Neurons and Potential Therapeutic Treatment of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Mineralocorticoid Receptor Blockade in the Protection of Target Organ Damage
Cardiovascular & Hematological Agents in Medicinal Chemistry Non-Covalent Proteasome Inhibitors
Current Pharmaceutical Design High Fat Meal Increase of IL-17 is Prevented by Ingestion of Fruit Juice Drink in Healthy Overweight Subjects
Current Pharmaceutical Design Aldose Reductase Inhibition: Emerging Drug Target for the Treatment of Cardiovascular Complications
Recent Patents on Cardiovascular Drug Discovery Modulation of Neutrophil Function by Hormones
Current Immunology Reviews (Discontinued) Oxidative Stress as a Regulator of Murine Atherosclerosis
Current Drug Targets Protein-Protein Interactions in Drug Discovery
Drug Design Reviews - Online (Discontinued) Potential Therapeutic Application of Chondroitin Sulfate/Dermatan Sulfate
Current Drug Discovery Technologies Platelet Glycoprotein IIb / IIIa Inhibition and its Clinical Use
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Discovery and Evaluation of Efficient Selenazoles with High Antifungal Activity Against Candida spp.
Medicinal Chemistry Possibility of Non-Immunosuppressive Immunophilin Ligands as Potential Therapeutic Agents for Parkinsons Disease
Current Pharmaceutical Design Potential Interactions of Carotenoids with Other Bioactive Food Components in the Prevention of Chronic Diseases
Current Bioactive Compounds New Insights into Acute and Chronic Lung Rejection
Current Respiratory Medicine Reviews Crocin Protects Against Beta-Amyloid Peptide-Induced Apoptosis in PC12 Cells Via the PI3 K Pathway
Current Molecular Pharmacology Clinical Use of Aspirin in Ischemic Heart Disease: Past, Present and Future
Current Pharmaceutical Design ULK1 Plays a Critical Role in AMPK-Mediated Myocardial Autophagy and Contractile Dysfunction following Acute Alcohol Challenge
Current Pharmaceutical Design MicroRNAs as Candidate Drug Targets for Cardiovascular Diseases
Current Drug Targets Medicinal and Beneficial Health Applications of Tinospora cordifolia (Guduchi): A Miraculous Herb Countering Various Diseases/Disorders and its Immunomodulatory Effects
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) AMPK as a New Attractive Therapeutic Target for Disease Prevention: The Role of Dietary Compounds AMPK and Disease Prevention
Current Drug Targets